NVNO Fail-to-Deliver

enVVeno Medical Corporation (NVNO) operates in the Healthcare sector, specifically the Medical - Devices industry, with a market capitalization near $178,893, listed on NASDAQ, employing roughly 37 people, carrying a beta of 1.09 to the broader market. enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. Led by Robert A. Berman, public since 2018-05-31.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Latest Date

2026-05-29

Latest FTD Quantity

146

Latest Price

$11.07

30-Day Avg FTD

638

30-Day Total FTD

19.1K

Showing 30 days of SEC fail-to-deliver data for enVVeno Medical Corporation.

Learn how fails-to-deliver is reported and how to read the data →

Frequently asked NVNO fail to deliver questions

What is the latest NVNO fail-to-deliver count?

As of May 29, 2026, enVVeno Medical Corporation (NVNO) fail-to-deliver quantity is 146 shares, with a 30-day average of 638 shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.

What is the FTD aggregate net balance?

FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.

How do NVNO FTDs affect options pricing?

Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.